...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Gynecologic Oncology: An International Journal >The efficacy of complex decongestive physiotherapy (CDP) and predictive factors of response to CDP in lower limb lymphedema (LLL) after pelvic cancer treatment
【24h】

The efficacy of complex decongestive physiotherapy (CDP) and predictive factors of response to CDP in lower limb lymphedema (LLL) after pelvic cancer treatment

机译：盆腔癌治疗后下肢淋巴水肿（LLL）的复杂性减充血理疗（CDP）的疗效和对CDP反应的预测因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: The aim of this study was to estimate the efficacy of an intensive CDP program, as well as to identify the predictors associated with lymphedema severity and response to CDP in lower limb lymphedema (LLL) after pelvic cancer therapy. Methods: We performed a retrospective review of post-pelvic cancer LLL patients that were treated with a CDP program between January 2004 and March 2011. Results: Twenty-seven (61.4%) of the total 44 patients had cervical cancer, 9 (20.5%) had endometrial cancer, and 8 (18.2%) had ovarian cancer. The mean age was 62.2 years, 18 (40.9%) patients received radiotherapy and a mean of 12.6 sessions of daily CDP, and mean lymphedema duration was 34.8 months. The interval from pelvic cancer treatment to LLL development was 63.4 months. Lymphedema severity, baseline and post-CDP percentage of excess volume (PEV) were 32.9% ± 18.4% and 18.8% ± 16.7%. Baseline PEV was not correlated with duration of lymphedema, number of CDP sessions, age or radiotherapy, and was significantly different to post-CDP PEV (p < 0.001). CDP efficacy, percentage reduction of excess volume (PREV), was - 55.1%, and was correlated with baseline PEV, but not with the number of CDP sessions, duration of lymphedema, or age. PEV (p < 0.001) was the only predictive factor for CDP efficacy. Conclusions: The key to predicting successful lymphedema treatment of LLL is the initial PEV. The intensive CDP program was effective and successful. We should encourage and refer patients to undergo treatment for LLL, even when the LLL is mild.
机译：目的：本研究的目的是评估强化CDP计划的疗效，并确定骨盆癌治疗后下肢淋巴水肿（LLL）中与淋巴水肿严重程度和对CDP反应相关的预测因子。方法：我们对2004年1月至2011年3月期间接受CDP程序治疗的盆腔癌后LLL患者进行了回顾性研究。结果：在44例宫颈癌患者中，有27例（61.4％），9例（20.5％） ）患有子宫内膜癌，其中8例（18.2％）患有卵巢癌。平均年龄为62.2岁，其中18例（40.9％）患者接受了放射治疗，平均每日CDP为12.6次，平均淋巴水肿持续时间为34.8个月。从盆腔癌治疗到LLL发展的间隔为63.4个月。淋巴水肿的严重程度，基线和CDP后过剩体积百分比（PEV）分别为32.9％±18.4％和18.8％±16.7％。基线PEV与淋巴水肿持续时间，CDP疗程数，年龄或放疗无关，与CDP后PEV显着不同（p <0.001）。 CDP功效，超量减少百分比（PREV）为-55.1％，与基线PEV相关，但与CDP疗程次数，淋巴水肿持续时间或年龄无关。 PEV（p <0.001）是CDP疗效的唯一预测因素。结论：预测成功的LLL淋巴水肿治疗的关键是初始PEV。密集的CDP计划有效且成功。即使LLL较轻，我们也应鼓励并转介患者接受LLL治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号